Seclidemstat

DRUG3 trials

Conditions

Angiomatoid Fibrous HistiocytomaChronic Myelomonocytic Leukemia-0Chronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Clear Cell SarcomaDesmoplastic Small Round Cell TumorEwing SarcomaExtraskeletal Myxoid Chondrosarcoma

Phase 1

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

NCT03600649

Salarius Pharmaceuticals, LLCAngiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Desmoplastic Small Round Cell Tumor +8

Start: 2018-06-04End: 2025-12-31Target: 50Updated: 2023-11-21

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Active, not recruitingNCT04734990

M.D. Anderson Cancer CenterChronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 +3

Start: 2021-07-07End: 2027-09-11Updated: 2026-04-02

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

NCT05266196

Salarius Pharmaceuticals, LLCAngiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Desmoplastic Small Round Cell Tumor +6

Start: 2022-01-15End: 2025-12-31Target: 10Updated: 2023-08-01

Cancer Research Communications2025-08-25

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Blood2022-11-154 citations

Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.

Journal of Clinical Oncology2021-05-2019 citations

Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.

Journal of Clinical Oncology2021-05-203 citations

Abstract PO-041: Genome-wide CRISPR/Cas9 screen reveals mitochondrial gene mutation as a driver for drug resistance in Ewing sarcoma

Cancer Research2020-12-01

A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma.

Journal of Clinical Oncology2020-05-208 citations

Abstract CT109: A Phase I dose escalation and expansion study of seclidemstat (SP-2577) a first-in class reversible LSD1 inhibitor for patients with relapsed or refractory Ewing sarcoma

Cancer Research2019-07-011 citations

Abstract CT109: A Phase I dose escalation and expansion study of seclidemstat (SP-2577) a first-in class reversible LSD1 inhibitor for patients with relapsed or refractory Ewing sarcoma

Clinical Trials2019-07-01

Seclidemstat

Sponsors

Conditions

Phase 1

Related Papers